PET/CT in Lymphoma: Current Overview and Future Directions

Area of Science:

• Oncology
• Nuclear Medicine
• Medical Imaging

Background:

• Positron Emission Tomography (PET) has become essential for staging and restaging lymphomas.
• Optimal use of PET in lymphoma management presents ongoing challenges, particularly for non-Hodgkin lymphoma.
• Risk-adapted strategies show promise in Hodgkin lymphoma but yield less convincing results in non-Hodgkin lymphoma.

Purpose of the Study:

• To review critical issues and potential improvements in the application of FDG/PET for lymphoma management.
• To explore novel strategies for integrating PET findings into treatment protocols.
• To address challenges posed by new immunomodulatory drugs on PET scan interpretation.

Main Methods:

• Review of current literature on FDG/PET in lymphoma staging and restaging.
• Discussion of risk-adapted strategies and their impact on patient outcomes.
• Exploration of advanced applications, including metabolic tumor volume assessment and biomarker integration.

Main Results:

• FDG/PET is crucial for accurate lymphoma staging, with risk-adapted strategies benefiting Hodgkin lymphoma.
• Results for non-Hodgkin lymphoma are less conclusive, highlighting a need for optimized approaches.
• New immunomodulatory drugs can cause false-positive scans, necessitating revised interpretation criteria for tumor flare reactions.

Conclusions:

• Integrating biomarker studies and understanding the tumor microenvironment can enhance PET's utility.
• Improving FDG/PET integration methods is key to advancing lymphoma patient care.
• Optimized PET application holds the potential to significantly improve patient outcomes in lymphoma management.